CurrentCareSourcePolicy N/A

Kanuma (sebelipase alfa) coverage for Lysosomal Acid Lipase (LAL) deficiency

This pharmacy policy governs prior-authorization coverage criteria for Kanuma (sebelipase alfa) when used to treat Lysosomal Acid Lipase (LAL) deficiency for CareSource members in Arkansas PASSE. It defines initial and reauthorization clinical requirements, dosing/quantity limits, and related administrative notes.

Policy Summary

PayerCareSource

PolicyKanuma (sebelipase alfa) coverage for Lysosomal Acid Lipase (LAL) deficiency

Policy CodePolicy N/A

Change TypeAnnual review — no material changes

Effective DateOct 1, 2024

Next Review DateOct 1, 2024

Key ActionObtain prior authorization for Kanuma under Arkansas PASSE before initiating treatment.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6 monthsinitial approval duration

12 monthsreauthorization approval duration

1 mg/kg q2wstandard starting dose

up to 5 mg/kg weeklymax infant dose

Prior Authorization Requiredcoverage status

Coverage Criteria for Kanuma (sebelipase alfa)

inv-01: Initial Therapy

Covered when ALL of the following are met:

Initial Authorization: 1) Member is at least 1 month of age; 2) Medication prescribed by or in consultation with a hepatologist, cardiologist, metabolic specialist, or geneticist; 3) Diagnosis of LAL deficiency confirmed by at least one of: (a) deficient LAL enzyme activity assay OR (b) identification of biallelic pathogenic LIPA mutations; 4) Member demonstrates at least one clinical feature of LAL deficiency such as dyslipidemia, elevated transaminases (ALT, AST), impaired growth/failure to thrive, malabsorption, hepatomegaly, adrenal calcification (Wolman disease), or advanced liver disease; 5) Dosing consistent with policy (see dosing criteria). If all above requirements are met, approve for 6 months.

Dosing detail captured in separate dosing criteria node

inv-02: Continuation Therapy / Reauthorization

Covered when ALL of the following are met:

Reauthorization: Chart notes must document a positive clinical response to treatment (e.g., improved lipid profile or other clinical improvement). If documented, approve medication for an additional 12 months.

Policy Summary

PayerCareSource

PolicyKanuma (sebelipase alfa) coverage for Lysosomal Acid Lipase (LAL) deficiency

Policy CodePolicy N/A

Change TypeAnnual review — no material changes

Effective DateOct 1, 2024

Next Review DateOct 1, 2024

Key ActionObtain prior authorization for Kanuma under Arkansas PASSE before initiating treatment.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Clinical response documentation required

CareSource considers treatment with Kanuma (sebelipase alfa) for any condition not listed in this document to be not medically necessary. Providers should refer to the plan's Off-Label policy for requests outside the approved indication of Lysosomal Acid Lipase (LAL) deficiency.

Use of Kanuma for indications other than Lysosomal Acid Lipase (LAL) deficiency (including Wolman disease and CESD as covered forms of LAL deficiency) is considered not medically necessary. Requests for Kanuma for other diagnoses will be reviewed against the Off-Label policy and are subject to denial.

Initial Therapy Dosing and Requirements

inv-12: Initial dosing

Initial dosing and criteria: Pediatric and adult LAL-D: 1 mg/kg IV infusion every other week; may increase to 3 mg/kg every other week if clinical response is suboptimal. Infants with rapidly progressive LAL-D (within first 6 months): start 1 mg/kg IV once weekly; may increase to 3 mg/kg once weekly and up to 5 mg/kg once weekly if needed.

Dosing and escalation per weight-based regimen; see quantity limits

Kanuma (sebelipase alfa) — dosing and escalation details (inv-15)

Standard pediatric & adult dose1 mg/kg IV every other week (standard starting dose)

Escalation option (pediatric & adult)May increase to 3 mg/kg IV every other week if clinical response is suboptimal

Infant starting dose (rapidly progressive within first 6 months)1 mg/kg IV once weekly

Infant escalation stepsIf suboptimal response, may increase to 3 mg/kg once weekly and further to 5 mg/kg once weekly if needed

Reauthorization and Ongoing Therapy

Reauthorization Criteria

Reauthorization — continuation criteria

Reauthorization (Continuation) — medication may be continued when ALL of the following are met:

Current prescriber documents ongoing management (prescribed by or in consultation with a hepatologist, cardiologist, metabolic specialist, or geneticist).
Chart notes document a positive clinical response to treatment (examples include improved lipid profile, decreased transaminases, improved growth or weight gain in pediatric patients, reduction in hepatomegaly, or stabilization/improvement of other disease manifestations).
Clinical response should be specific and measurable where possible (eg, numeric change in LDL/ triglycerides, ALT/AST).
Member continues to meet diagnostic criteria for LAL deficiency (documented deficient LAL enzyme activity assay and/or identification of biallelic pathogenic LIPA mutations).
No documentation of unacceptable adverse effects or contraindications that would warrant discontinuation of therapy.
Therapy has been used within the approved dosing limits (pediatric/adult: 1 mg/kg IV every other week, may increase to 3 mg/kg every other week if suboptimal response; infants with rapidly progressive disease: start 1 mg/kg weekly, may increase to 3 mg/kg or up to 5 mg/kg weekly if needed).
Dose adjustments should be supported by clinical rationale and documented response.
Request for reauthorization is submitted prior to or at the end of the current approval period with supporting chart documentation.

Prior Authorization

Prior Authorization and Documentation Requirements

Provider action: Prior authorization requirement; Provider action: Not covered indications; Provider action: Documentation requirements for reauthorization.

Prior authorization is required for initial and continued coverage of sebelipase alfa (Kanuma).
For reauthorization, submit chart notes documenting diagnosis confirmation and positive clinical response as described in the continuation criteria.
Kanuma is not covered for indications not listed in this policy (off-label uses) — submiters should refer to the payer's Off-Label policy for exception processes.

Provider Requirements and Administrative Notes

Prior Authorization

Prior authorization required (medical benefit)

Kanuma (sebelipase alfa) is covered as a medical benefit and prior authorization is required for coverage under Arkansas PASSE.

Submit prior authorization for Kanuma (sebelipase alfa) under the medical benefit for Arkansas PASSE.

Billing Rule

Provider billing note

Ensure claims/billing reflect Kanuma as a medical benefit and follow payer prior-authorization procedures; contact CareSource for any claim or coding questions.

Bill under the medical benefit (Kanuma = Medical).
Follow prior authorization submission requirements per Arkansas PASSE.

Denial Risk

Not covered — off‑label indications

Coverage will be denied for use of Kanuma for indications not listed in this policy; use for off‑label indications is considered not medically necessary per the Off‑Label policy.

Do not expect coverage when Kanuma is prescribed for conditions outside those listed in this document (refer to Off‑Label policy).

Dosing Limits and Quantity Guidance

Kanuma (sebelipase alfa) — dosing per weight (inv-15)

Standard dose (pediatric & adult)1 mg/kg IV every other week

Permitted escalation (pediatric & adult)Increase to 3 mg/kg IV every other week if clinical response is suboptimal

Infant dosing pathwayInfants with rapidly progressive disease: start 1 mg/kg IV once weekly; may increase to 3 mg/kg and up to 5 mg/kg once weekly if needed

Site of Care and Infusion Notes

Note

Infusion site‑of‑care

No explicit site‑of‑care restrictions are stated in the policy; Kanuma is administered by IV infusion (infusion center setting noted).

Policy lists Kanuma as medical benefit and describes IV infusion dosing but does not restrict infusion location.

Definitions and Disease Phenotypes

Wolman disease (inv-10)

DefinitionWolman disease: the early infantile-onset, rapidly progressive phenotype of LAL deficiency with survival not expected beyond infancy without treatment

Typical featuresRapid progression in infancy; adrenal calcification may be present

Prognosis without treatmentPoor survival beyond infancy; Kanuma significantly prolongs life expectancy

CESD — Cholesterol ester storage disease (inv-11)

DefinitionCholesterol ester storage disease (CESD): a later-onset, more variable phenotype of LAL deficiency presenting in childhood or adulthood

Clinical courseVariable presentation and severity compared with Wolman disease

Treatment relevanceKanuma has demonstrated benefits for patients with CESD

Background

Lysosomal Acid Lipase (LAL) deficiency is a genetic lysosomal storage disorder caused by pathogenic variants in the LIPA gene resulting in absent or reduced lysosomal acid lipase activity and accumulation of cholesteryl esters and triglycerides in tissues. Clinical features span a spectrum from the rapidly progressive infantile form (Wolman disease) with poor survival if untreated to later-onset Cholesteryl Ester Storage Disease (CESD). Manifestations commonly include dyslipidemia, elevated transaminases, hepatomegaly, malabsorption, growth failure, and, in infants, adrenal calcification. Kanuma (sebelipase alfa) is an enzyme replacement therapy approved to treat LAL deficiency by addressing the underlying enzyme defect.

Step Therapy Requirements

Step	Requirement
1	No step therapy requirements specified.
Coverage label	Prior authorization required — Kanuma (sebelipase alfa) is a medical benefit and requires prior authorization under Arkansas PASSE.